Swiss pharma firm Lonza reports half-year profit decline due to weak capsule demand, one-off payments, and weaker Swiss franc; shares rise 3.5%.
Lonza, a Swiss pharma firm, reported a decline in its half-year profit, affected by weak demand for capsules and health ingredients, one-off payments, and a weaker Swiss franc. Despite this, the profit surpassed market expectations, leading to a 3.5% increase in the company's shares. The demand for pharmaceutical supplies such as hard capsules and lab equipment fell from pandemic peak levels, impacting Lonza's sales.
July 25, 2024
3 Articles